Exploring the Risks and Rewards of Weight Loss Drugs: What You Need to Know
In recent years, the demand for weight loss drugs such as Wegovy/Ozempic and Mounjaro has been steadily increasing in western countries. While these medications have gained popularity for their ability to aid in weight loss, concerns have emerged regarding the availability of ready supplies to meet the growing demand.
Despite their effectiveness, weight loss jabs like GLP-1 receptor agonists come with a range of potential side effects. Common gastrointestinal issues such as nausea, vomiting, and constipation are often reported by users. Additionally, the phenomenon known as “Ozempic face,” which refers to a gaunt, aged appearance resulting from rapid weight loss, has raised eyebrows among health professionals.
While the most common side effects are manageable, more serious concerns have been raised about potential links to eye disease, reduced libido, and an increased risk of certain cancers. Thyroid cancer, in particular, has been a focus of study, with some evidence suggesting a possible association with GLP-1 drugs.
It is essential to note that weight loss injections like Wegovy and Ozempic, which contain semaglutide, were originally developed for treating type 2 diabetes. These medications work by activating receptors in the pancreas to regulate insulin release and reduce blood sugar levels, leading to weight loss through appetite suppression.
On the other hand, Mounjaro, which contains tirzepatide, acts on both the GLP-1 and GIP receptors to enhance insulin production and improve insulin sensitivity. This dual action results in significant weight loss, making it a promising option for combating obesity.
While tirzepatide has shown promise in clinical trials and even demonstrated potential tumor-shrinking effects in certain cancers, the long-term effects and risks associated with these drugs require further investigation.
Understanding the Relationship Between Weight Loss Drugs and Cancer Risk
Obesity itself is a known risk factor for various cancers, and by facilitating weight loss, GLP-1 drugs could indirectly reduce the risk of obesity-related cancer development. Some studies have even suggested lower rates of obesity-related cancers in individuals using GLP-1 medications.
However, the exact mechanism behind this risk reduction remains unclear, and more research is needed to determine whether the protective effect is linked to the drugs’ action or the weight loss itself.
Overall, while the risk of cancer associated with GLP-1 drugs appears to be low, caution is advised for individuals with a history of thyroid cancer or certain endocrine conditions that may increase sensitivity to hormone-related tumor growth.
Weight loss injections offer a potential solution for individuals struggling with obesity, but it is essential to weigh the benefits against the possible risks. As research continues to uncover the true impact of these medications on health and well-being, the conversation surrounding weight loss drugs remains ongoing.
Nadine Wehida, Senior Lecturer in Genetics and Molecular Biology, Kingston University and Ahmed Elbediwy, Senior Lecturer in Clinical Biochemistry / Cancer Biology, Kingston University
This article is republished from The Conversation under a Creative Commons license. Read the original article here.
